These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 25957377)

  • 1. A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab.
    Saunders DJ; Muether PS; Fauser S
    Br J Ophthalmol; 2015 Nov; 99(11):1554-9. PubMed ID: 25957377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
    Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration.
    Muether PS; Hermann MM; Dröge K; Kirchhof B; Fauser S
    Am J Ophthalmol; 2013 Nov; 156(5):989-993.e2. PubMed ID: 23938122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
    Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
    Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors.
    Krohne TU; Muether PS; Stratmann NK; Holz FG; Kirchhof B; Meyer CH; Fauser S
    Retina; 2015 Jan; 35(1):69-74. PubMed ID: 25077535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.
    Fauser S; Muether PS
    Br J Ophthalmol; 2016 Nov; 100(11):1494-1498. PubMed ID: 26888975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Caruso A; Maini PK; Mazer NA
    Mol Pharm; 2018 Jul; 15(7):2770-2784. PubMed ID: 29734810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration.
    Fauser S; Viebahn U; Muether PS
    Acta Ophthalmol; 2015 Dec; 93(8):734-8. PubMed ID: 26016605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration.
    Wang X; Sawada T; Kakinoki M; Miyake T; Kawamura H; Saishin Y; Liu P; Ohji M
    Graefes Arch Clin Exp Ophthalmol; 2014 Jul; 252(7):1033-9. PubMed ID: 24196779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of posterior vitreous detachment on aqueous humor level of vascular endothelial growth factor in exudative age-related macular degeneration patients.
    Nomura Y; Takahashi H; Tan X; Fujino Y; Kawashima H; Yanagi Y
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):53-7. PubMed ID: 25863675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.
    Sakurada Y; Nakamura Y; Yoneyama S; Mabuchi F; Gotoh T; Tateno Y; Sugiyama A; Kubota T; Iijima H
    Ophthalmic Res; 2015; 53(1):2-7. PubMed ID: 25472810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Aqueous Flare Levels Following Intravitreal Ranibizumab Injection for Neovascular Age-related Macular Degeneration.
    Uzun A; Yalcindag FN; Demirel S; Batýoðlu F; Ozmert E
    Ocul Immunol Inflamm; 2017 Apr; 25(2):229-232. PubMed ID: 26828124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor suppression times in patients with diabetic macular oedema treated with ranibizumab.
    Muether PS; Droege KM; Fauser S
    Br J Ophthalmol; 2014 Feb; 98(2):179-81. PubMed ID: 24227804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes.
    Niwa Y; Kakinoki M; Sawada T; Wang X; Ohji M
    Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6501-5. PubMed ID: 26447985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
    Gaudreault J; Fei D; Beyer JC; Ryan A; Rangell L; Shiu V; Damico LA
    Retina; 2007; 27(9):1260-6. PubMed ID: 18046235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study.
    dell'Omo R; Cassetta M; dell'Omo E; di Salvatore A; Hughes JM; Aceto F; Porcellini A; Costagliola C
    Am J Ophthalmol; 2012 Jan; 153(1):155-61.e2. PubMed ID: 21861975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization.
    Sun T; Wei Q; Gao P; Zhang Y; Peng Q
    Drug Des Devel Ther; 2021; 15():2457-2467. PubMed ID: 34140764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy.
    Sakamoto S; Takahashi H; Tan X; Inoue Y; Nomura Y; Arai Y; Fujino Y; Kawashima H; Yanagi Y
    Br J Ophthalmol; 2018 Apr; 102(4):448-454. PubMed ID: 28765149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.